- Home
- Publications
- Publication Search
- Publication Details
Title
Therapeutic targeting of IL-6 trans-signaling
Authors
Keywords
Cytokine, Cytokine receptor, Interleukin-6, GP130, Trans-signaling, Soluble receptor, blood-buffer
Journal
CYTOKINE
Volume 144, Issue -, Pages 155577
Publisher
Elsevier BV
Online
2021-05-19
DOI
10.1016/j.cyto.2021.155577
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Transneuronal delivery of hyper-interleukin-6 enables functional recovery after severe spinal cord injury in mice
- (2021) Marco Leibinger et al. Nature Communications
- Control of RNA Stability in Immunity
- (2021) Shizuo Akira et al. Annual Review of Immunology
- Therapeutic IL-6 trans-signalling inhibition by olamkicept (sgp130Fc) in patients with active inflammatory bowel disease
- (2021) Stefan Schreiber et al. GASTROENTEROLOGY
- Natural Glycoforms of Human Interleukin 6 Show Atypical Plasma Clearance
- (2021) Andreas Reif et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Repopulating Microglia Promote Brain Repair in an IL-6-Dependent Manner
- (2020) Emily F. Willis et al. CELL
- Biological functions and therapeutic opportunities of soluble cytokine receptors
- (2020) Juliane Lokau et al. CYTOKINE & GROWTH FACTOR REVIEWS
- Dominant-negative mutations in human IL6ST underlie hyper-IgE syndrome
- (2020) Vivien Béziat et al. JOURNAL OF EXPERIMENTAL MEDICINE
- IL-18BP is a secreted immune checkpoint and barrier to IL-18 immunotherapy
- (2020) Ting Zhou et al. NATURE
- Cathepsin S provokes interleukin-6 (IL-6) trans-signaling through cleavage of the IL-6 receptor in vitro
- (2020) Charlotte M. Flynn et al. Scientific Reports
- Enhanced IL-36R signaling promotes barrier impairment and inflammation in skin and intestine
- (2020) Zaruhi Hovhannisyan et al. Science Immunology
- ADAM17 selectively activates the IL‐6 trans‐signaling/ERK MAPK axis in KRAS‐addicted lung cancer
- (2019) Mohamed I Saad et al. EMBO Molecular Medicine
- Targeting Interleukin-6 Signaling in Clinic
- (2019) Sujin Kang et al. IMMUNITY
- The IL-6-neutralizing sIL-6R/sgp130 buffer system is disturbed in patients with type 2 diabetes
- (2019) Samadhi Aparicio-Siegmund et al. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
- Loss of the interleukin-6 receptor causes immunodeficiency, atopy, and abnormal inflammatory responses
- (2019) Sarah Spencer et al. JOURNAL OF EXPERIMENTAL MEDICINE
- ADAM17 Activity and IL-6 Trans-Signaling in Inflammation and Cancer
- (2019) Schumacher et al. Cancers
- ADAM17 is required for EGF-R–induced intestinal tumors via IL-6 trans-signaling
- (2018) Stefanie Schmidt et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Interleukin-6: designing specific therapeutics for a complex cytokine
- (2018) Christoph Garbers et al. NATURE REVIEWS DRUG DISCOVERY
- The role of IL-6 in host defence against infections: immunobiology and clinical implications
- (2017) Stefan Rose-John et al. Nature Reviews Rheumatology
- Interleukin-6 Family Cytokines
- (2017) Stefan Rose-John Cold Spring Harbor Perspectives in Biology
- Proteolytic Origin of the Soluble Human IL-6R In Vivo and a Decisive Role of N-Glycosylation
- (2017) Steffen Riethmueller et al. PLOS BIOLOGY
- Meprin Metalloproteases Generate Biologically Active Soluble Interleukin-6 Receptor to Induce Trans-Signaling
- (2017) Philipp Arnold et al. Scientific Reports
- Quantitative proteomics screen identifies a substrate repertoire of rhomboid protease RHBDL2 in human cells and implicates it in epithelial homeostasis
- (2017) Nicholas Johnson et al. Scientific Reports
- Therapeutic Targeting of the IL-6 Trans-Signaling/Mechanistic Target of Rapamycin Complex 1 Axis in Pulmonary Emphysema
- (2016) Saleela M. Ruwanpura et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial
- (2016) Gerd R Burmester et al. ANNALS OF THE RHEUMATIC DISEASES
- IL-6 trans-signaling is essential for the development of hepatocellular carcinoma in mice
- (2016) Juri Bergmann et al. HEPATOLOGY
- A pathogenic role for T cell–derived IL-22BP in inflammatory bowel disease
- (2016) Penelope Pelczar et al. SCIENCE
- Insights into Cytokine–Receptor Interactions from Cytokine Engineering
- (2015) Jamie B. Spangler et al. Annual Review of Immunology
- Blocking IL-6 trans-Signaling Prevents High-Fat Diet-Induced Adipose Tissue Macrophage Recruitment but Does Not Improve Insulin Resistance
- (2015) Michael J. Kraakman et al. Cell Metabolism
- The IL-6/gp130/STAT3 signaling axis: recent advances towards specific inhibition
- (2015) Christoph Garbers et al. CURRENT OPINION IN IMMUNOLOGY
- Shedding of Endogenous Interleukin-6 Receptor (IL-6R) Is Governed by A Disintegrin and Metalloproteinase (ADAM) Proteases while a Full-length IL-6R Isoform Localizes to Circulating Microvesicles
- (2015) Neele Schumacher et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- IL-6 Trans-Signaling Drives Murine Crescentic GN
- (2015) G. S. Braun et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- IL-6 as a keystone cytokine in health and disease
- (2015) Christopher A Hunter et al. NATURE IMMUNOLOGY
- Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials
- (2015) Vibeke Strand et al. ARTHRITIS RESEARCH & THERAPY
- The interleukin-6 receptor Asp358Ala single nucleotide polymorphism rs2228145 confers increased proteolytic conversion rates by ADAM proteases
- (2014) Christoph Garbers et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- Therapeutic Targeting of IL-6 Trans Signaling Counteracts STAT3 Control of Experimental Inflammatory Arthritis
- (2014) M. A. Nowell et al. JOURNAL OF IMMUNOLOGY
- IL-6 in Inflammation, Immunity, and Disease
- (2014) T. Tanaka et al. Cold Spring Harbor Perspectives in Biology
- Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial
- (2013) Cem Gabay et al. LANCET
- New targets for mucosal healing and therapy in inflammatory bowel diseases
- (2013) M F Neurath Mucosal Immunology
- Arid5a controls IL-6 mRNA stability, which contributes to elevation of IL-6 level in vivo
- (2013) Kazuya Masuda et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Functional IL6R 358Ala Allele Impairs Classical IL-6 Receptor Signaling and Influences Risk of Diverse Inflammatory Diseases
- (2013) Ricardo C. Ferreira et al. PLoS Genetics
- Therapeutic targeting of interleukin-6 trans-signaling does not affect the outcome of experimental tuberculosis
- (2012) Jan Sodenkamp et al. IMMUNOBIOLOGY
- IL-6 Controls the Innate Immune Response against Listeria monocytogenes via Classical IL-6 Signaling
- (2012) J. Hoge et al. JOURNAL OF IMMUNOLOGY
- The interleukin 6 pathway and atherosclerosis
- (2012) Jürgen Scheller et al. LANCET
- Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies
- (2012) LANCET
- Transsignaling of Interleukin-6 Crucially Contributes to Atherosclerosis in Mice
- (2011) Harald Schuett et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Stat3/Socs3 Activation by IL-6 Transsignaling Promotes Progression of Pancreatic Intraepithelial Neoplasia and Development of Pancreatic Cancer
- (2011) Marina Lesina et al. CANCER CELL
- Selective blockade of interleukin-6 trans-signaling improves survival in a murine polymicrobial sepsis model*
- (2011) Tanja Barkhausen et al. CRITICAL CARE MEDICINE
- Species Specificity of ADAM10 and ADAM17 Proteins in Interleukin-6 (IL-6) Trans-signaling and Novel Role of ADAM10 in Inducible IL-6 Receptor Shedding
- (2011) Christoph Garbers et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Inhibition of Classic Signaling Is a Novel Function of Soluble Glycoprotein 130 (sgp130), Which Is Controlled by the Ratio of Interleukin 6 and Soluble Interleukin 6 Receptor
- (2011) Christoph Garbers et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Interleukin-36–Receptor Antagonist Deficiency and Generalized Pustular Psoriasis
- (2011) Slaheddine Marrakchi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Insulin-sensitive obesity
- (2010) Nora Klöting et al. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
- The soluble Interleukin 6 receptor: Generation and role in inflammation and cancer
- (2010) Athena Chalaris et al. EUROPEAN JOURNAL OF CELL BIOLOGY
- IL-6 Trans-Signaling Modulates TLR4-Dependent Inflammatory Responses via STAT3
- (2010) C. J. Greenhill et al. JOURNAL OF IMMUNOLOGY
- IL-1 family nomenclature
- (2010) Charles Dinarello et al. NATURE IMMUNOLOGY
- IL-6 and Stat3 Are Required for Survival of Intestinal Epithelial Cells and Development of Colitis-Associated Cancer
- (2009) Sergei Grivennikov et al. CANCER CELL
- Zc3h12a is an RNase essential for controlling immune responses by regulating mRNA decay
- (2009) Kazufumi Matsushita et al. NATURE
- Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease
- (2008) N. Nishimoto et al. BLOOD
- Structure-guided Optimization of the Interleukin-6 Trans-signaling Antagonist sgp130
- (2008) Stephanie Tenhumberg et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Structural Biology of Shared Cytokine Receptors
- (2007) Xinquan Wang et al. Annual Review of Immunology
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started